Title:
RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS
Document Type and Number:
WIPO Patent Application WO2003023042
Kind Code:
A9
Abstract:
The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.
Inventors:
SUTTER GERD (DE)
ERFLE VOLKER (DE)
STAIB CAROLINE (DE)
WANG YUAN (CN)
LI GUANGDI (CN)
ZHU LIXIN (CN)
ERFLE VOLKER (DE)
STAIB CAROLINE (DE)
WANG YUAN (CN)
LI GUANGDI (CN)
ZHU LIXIN (CN)
Application Number:
PCT/EP2002/009958
Publication Date:
December 11, 2003
Filing Date:
September 05, 2002
Export Citation:
Assignee:
GSF FORSCHUNGSZENTRUM UMWELT (DE)
SUTTER GERD (DE)
ERFLE VOLKER (DE)
STAIB CAROLINE (DE)
WANG YUAN (CN)
LI GUANGDI (CN)
ZHU LIXIN (CN)
SUTTER GERD (DE)
ERFLE VOLKER (DE)
STAIB CAROLINE (DE)
WANG YUAN (CN)
LI GUANGDI (CN)
ZHU LIXIN (CN)
International Classes:
C12N15/09; A61K39/29; A61P1/16; A61P31/12; A61P31/14; A61P35/00; A61P37/04; C12N5/10; C12N7/01; C12N7/04; C12N15/39; C12N15/51; C12N15/863; C12P21/02; A61K39/00; (IPC1-7): C12N15/863; C12N15/39; C12N15/51; C12N5/10; A61K39/285; A61K39/29
Download PDF: